Biogen Idec pursues the creativity of science with passion and discipline. For more than 25 years, the company has grown through the discovery, development and commercialization of its own innovative products and through strategic alliances.

Scientific excellence that achieves new standards of care drives the company's work. 16 products are currently in clinical development addressing a variety of key medical needs.

With patients in more than 90 countries, two blockbuster drugs lead Biogen Idec's product lineup:

RITUXAN® (rituximab) is the world's first licensed monoclonal antibody therapy for the treatment of certain B-cell non-Hodgkin's lymphomas (NHL). Additionally, RITUXAN is indicated for moderately-to-severely active rheumatoid arthritis. The company co-promotes the product in the United States with Genentech, Inc. Outside of the US, RITUXAN is marketed by Roche.

AVONEX® (interferon beta 1-a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) and is the most prescribed product in MS worldwide with over 130,000 patients on therapy.

Additionally, TYSABRI® (natalizumab) is the first monoclonal antibody approved for the treatment of relapsing remitting forms of MS and is currently marketed in both Europe and the US.

Zevalin® (ibritumomab tiuxetan) is a radioimmunotherapy for use in patients with relapsed or refractory, low-grade, follicular B-cell NHL.

In addition to Biogen Idec's promising portfolio of drug candidates, the company's capabilities and capacity for protein manufacturing are world-class in quality and scale. The company is one of a handful of biotechnology companies that has three licensed and dedicated biological bulk-manufacturing facilities, including its large-scale manufacturing plant in Research Triangle Park, NC, which is one of the world's largest cell culture facilities. An additional large-scale manufacturing plant is under construction in Hillerød, Denmark. Biogen Idec has sufficient commercial manufacturing capacity for its own pipeline, as well as potential partners' products.

Biogen Idec is headquartered in Cambridge, MA and was formed in 2003 from the merger of two of the world's leading biotechnology companies, Biogen, Inc., founded in Switzerland in 1978, and IDEC Pharmaceuticals Corporation, founded in San Francisco, CA in 1985.

The company maintains research centers of excellence in San Diego, CA and Cambridge, MA. Biogen Idec has additional offices in Canada, Australia, Japan and throughout Europe, including international headquarters in Zug, Switzerland. The company currently employs approximately 3,400 people worldwide.